Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings

This study has been completed.
Information provided by:
Meir Medical Center Identifier:
First received: May 21, 2008
Last updated: May 23, 2008
Last verified: March 2004
Maintenance venom immunotherapy administered at 6-month intervals to bee-venom allergic patients failed to provide protection from systemic reactions after sting challenges. These patients should continue their immunotherapy at 1-3 month intervals.

Condition Intervention Phase
Venom Allergy
Drug: venom immunotherapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • whether the administration of bee venom (BV)
  • maintenance dose (MD) at 6-month interval is safe and
  • efficacious.

Estimated Enrollment: 60
Study Start Date: June 2004
Estimated Study Completion Date: May 2006
Detailed Description:

Background: The intervals at which maintenance venom immunotherapy (MVIT) is administered have been progressively extended over the years.

Objective: To examine whether the administration of bee venom (BV) maintenance dose (MD) at 6-month interval is safe and efficacious.

Methods: The usual 3-month interval at which venom allergic patients were receiving their MVIT was gradually extended to 6 months. Systemic reactions (SRs) to immunotherapy injections or to field stings were regularly recorded. BV allergic patients were deliberately sting-challenged after reaching the 6-month interval.


Ages Eligible for Study:   6 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Venom allergy

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00684476

Sponsors and Collaborators
Meir Medical Center
Principal Investigator: Arnon Goldberg, M.D The Allergy and Clinical Immunology Unit, Meir Hospital, Kfar-Saba, Israel, affiliated with The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
  More Information Identifier: NCT00684476     History of Changes
Other Study ID Numbers: 130504
Study First Received: May 21, 2008
Last Updated: May 23, 2008 processed this record on April 28, 2017